Results 41 to 50 of about 1,394,911 (165)

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Mechanisms and therapeutic prospects of thrombopoietin receptor agonists

, 2019
The second-generation thrombopoietin (TPO) receptor agonists eltrombopag and romiplostim are potent activators of megakaryopoiesis and represent a growing treatment option for patients with thrombocytopenic hematological disorders.
Kulasekararaj, Austin,, Bussel, James, Bussel, James,, Kulasekararaj, Austin, Semple, John W., Verma, Amit,, Semple, John W.,, Will, Britta, Steidl, Ulrich,, Verma, Amit, Cooper, Nichola,, Cooper, Nichola, Will, Britta,, Steidl, Ulrich, Lund University.   +14 more
core   +1 more source

Purpurin Alleviates Chemotherapy‐Induced Thrombocytopenia Through Estrogen Receptor α Dependent Phosphoinositide 3‐Kinase/Protein Kinase B Signalling

Phytotherapy Research, EarlyView.
Schematic overview of the in vitro and in vivo evaluation of purpurin in promoting MK maturation and platelet production, through ESR1/PI3K/AKT. ABSTRACT Chemotherapy‐induced thrombocytopenia (CIT) increases bleeding risk and compromises chemotherapy delivery.
Xiaolin Gan, Xinle Wang, Lu Hao, Xiaoqin Tang, Zhixuan Liu, Long Wang, Xiang Xie, Xiang Li, Chunling Zhao, Yan Li, Xinwu Huang, Yuanzhi Liu, Jianming Wu   +12 more
wiley   +1 more source

Pharmacist intervention through protocol-based pharmacotherapy management is effective to ensure safety in invasive procedures for chronic liver disease

Journal of Pharmaceutical Health Care and Sciences
Background The risk of hemorrhagic complications in patients with chronic liver disease during invasive procedures should be considered. Patients with low platelet counts were administered platelet products prior to procedures based on a physician's ...
Yuuka Shibata, Yuki Koga, Yuki Sato, Emiko Mashida, Tomokazu Kawaoka, Eisuke Murakami, Kei Amioka, Yusuke Johira, Kensuke Naruto, Takanori Taogoshi, Tomoharu Yokooji, Masataka Tsuge, Hiroaki Matsuo   +12 more
doaj   +1 more source

Increased anergic B cells and decreased antibody‐secreting cells during romiplostim treatment in patients with immune thrombocytopenia

British Journal of Haematology, EarlyView.
Summary Patients with immune thrombocytopenia (ITP) exhibit substantial heterogeneity in treatment responses. Approximately 30%–50% of patients maintain remission after discontinuation of thrombopoietin receptor agonists (TPO‐RA), suggesting immunomodulatory effects beyond enhanced thrombopoiesis.
Vivianne S. Nelson, Rebeca Gutiérrez‐Cózar, Rebecca Cornelis, S. Marieke van Ham, Anja ten Brinke, Rick Kapur   +5 more
wiley   +1 more source

Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia

Journal of Blood Medicine, 2016
Prakash Vishnu,1 David M Aboulafia1,2 1Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center, 2Division of Hematology, University of Washington, Seattle, WA, USA Abstract: Inhibition of platelet production and mediated by ...
Vishnu P, Aboulafia DM
doaj  

Repeated successful use of eltrombopag in chronic primary immune thrombocytopenia: description of an intriguing case

Clinical Case Reports, 2017
Key Clinical Message Thrombopoietin receptor agonists (TPO‐RAs) are used as effective alternative treatments in ITP patients unresponsive to first‐/second‐line therapies.
Cristina Santoro, Paola Volpicelli, Erminia Baldacci, Grazia Ferrara, Alice Di Rocco, Antonietta Ferretti, Marika Porrazzo, Maria Gabriella Mazzucconi   +7 more
doaj   +1 more source

Thrombopoietin Receptor Levels in Tumor Cell Lines and Primary Tumors [PDF]

, 2010
Thrombopoietin (TPO) receptor agonists represent a new approach for the treatment of thrombocytopenia, which may develop as a consequence of immune thrombocytopenia, chemotherapy treatment, chronic hepatitis C infection, or myelodysplastic syndromes ...
Anne-Marie Martin, Conrad Messam, Iman El-Hariry, Yuan Liu, Kodandaram Pillarisetti, Antony Chadderton, Yasser Mostafa Kamel, Anna Gibbard, Jennifer Kirchner, Connie L. Erickson-Miller, Lini Pandite, Katherine Baker   +11 more
core   +1 more source

Thrombopoietin receptor agonists increase splenic regulatory T-cell numbers in immune thrombocytopenia

, 2022
Thrombopoietin receptor agonists (TPO-RA) are a valid therapy for immune thrombocytopenia (ITP), due to megakaryocyte stimulation and (poorly characterised) immune-modulatory effects.
Rita Bresciani, Fabio d'Amore, Vincenza Guzzardo, Marco Pizzi, Barbara Famengo, Sbaraglia, Marta, Bresciani, Rita, Bertozzi, Irene, Alberto Friziero, Angelo Paolo Dei Tos, Auteri, Giuseppe, Nichele, Ilaria, Dei Tos, Angelo Paolo, Ilaria Nichele, Famengo, Barbara, Giuseppe Auteri, Guzzardo, Vincenza, Fabrizio Vianello, d'Amore, Emanuele S G, Pizzi, Marco, Vianelli, Nicola, Vianello, Fabrizio, Binotto, Gianni, Friziero, Alberto, Marta Sbaraglia, Carli, Giuseppe, Sabattini, Elena, Nicola Vianelli, Irene Bertozzi, Zoletto, Simone, Simone Zoletto, Federico Scarmozzino, Gianni Binotto, Emanuele S. G. d'Amore, d'Amore, Fabio, Giuseppe Carli, Elena Sabattini, Scarmozzino, Federico   +37 more
core   +1 more source

Personalized Management of Cytopenias in Chronic Liver Disease: From Pathophysiology to Treatment Strategies

JGH Open
Thrombocytopenia and leukopenia are among the most common hematological abnormalities in patients with chronic liver disease (CLD), particularly among those with cirrhosis.
Xiaoxiao Wang, Shuyan Fu, Xiaohong Zhu, Yanping Zhao   +3 more
doaj   +1 more source